A multi-platform analysis of paired well- and dedifferentiated liposarcoma identifies recurrent genomic alterations associated with progression and recurrence

Knowledge regarding genomic aberrations resulting in progression of low-grade well-differentiated liposarcoma (WDLS) to high-grade dedifferentiated liposarcoma (DDLS) is limited. We analyzed DNA sequence, copy number, and gene expression in 9 paired WD/DDLS or WD/WDLS serial surgical samples to identify potential drivers of progression. We validated the relevance of events using samples collected from 265 patients and in vitro studies. All WDLS exhibited characteristic amplification of 12q13-15; additional, novel 6q23-25 gains were observed in 18% of WDLS and associated with higher local recurrence risk (HR=11, p<0.001). The 6q23-25 amplicon encoded TAB2, which was 2.1-fold overexpressed in WDLS samples with the event; in vitro TAB2 was necessary to prevent senescence and allow for MDM2 accumulation in 6q23-25-amplified WDLS cells but not in non-amplified WDLS or amplified DDLS cells. WDLS progression to DDLS was not associated with 6q23-25 amplification but with pathogenic ATRX mutations (7.6% vs 0%), 13q losses (22% vs 3.4%), and 8q12-21 gains (21% vs 5%). Downregulation of 13q genes MYCBP2 and IRS2 was observed in DDLS; in vitro, these genes were essential for WDLS cell differentiation. This study defines a longitudinal model of liposarcomagenesis with initiation characterized by 12q13-15 amplification, early WDLS progression through inhibition of senescence by 6q23-25 amplification, and progression to DDLS driven by ATRX mutations and/or tertiary copy number events (e.g., 13q loss, 8q12-21 gain). Implications: This study defines the role of recurrent copy number alterations and gene mutations in WD/DDLS initiation and progression, creating a detailed map of molecular events regulating liposarcomagenesis, patient outcome, and dedifferentiation.

Authors

Institutions

Publication Details

Journal
Molecular Cancer Research
Published
2026-11-18
DOI
https://doi.org/10.1158/1541-7786.mcr-25-1363
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A multi-platform analysis of paired well- and dedifferentiated liposarcoma identifies recurrent genomic alterations associated with progression and recurrence

Li‐Xuan Qin, Cyriac Kandoth, Tianjie Pu, Kalyani Chadalavada et al.
Molecular Cancer Research
Sarcoma Diagnosis and Treatment
article

A multi-platform analysis of paired well- and dedifferentiated liposarcoma identifies recurrent genomic alterations associated with progression and recurrence

Li‐Xuan Qin, Cyriac Kandoth, Tianjie Pu, Kalyani Chadalavada, Jia Hu, Aimee Marie Crago, Penelope D. Ruiz, Nicholas D. Socci, Phaedra Agius, Agnes J. Viale, Amanda J. Craig, Rachael O’Connor, Winan J. van Houdt, Samuel Singer, Lakshana Senthilkumar, Alexander Lofthus, Nils Weinhold, Cristina R. Antonescu, Tomoyo Okada
article en

Abstract

Knowledge regarding genomic aberrations resulting in progression of low-grade well-differentiated liposarcoma (WDLS) to high-grade dedifferentiated liposarcoma (DDLS) is limited. We analyzed DNA sequence, copy number, and gene expression in 9 paired WD/DDLS or WD/WDLS serial surgical samples to identify potential drivers of progression. We validated the relevance of events using samples collected from 265 patients and in vitro studies. All WDLS exhibited characteristic amplification of 12q13-15; additional, novel 6q23-25 gains were observed in 18% of WDLS and associated with higher local recurrence risk (HR=11, p<0.001). The 6q23-25 amplicon encoded TAB2, which was 2.1-fold overexpressed in WDLS samples with the event; in vitro TAB2 was necessary to prevent senescence and allow for MDM2 accumulation in 6q23-25-amplified WDLS cells but not in non-amplified WDLS or amplified DDLS cells. WDLS progression to DDLS was not associated with 6q23-25 amplification but with pathogenic ATRX mutations (7.6% vs 0%), 13q losses (22% vs 3.4%), and 8q12-21 gains (21% vs 5%). Downregulation of 13q genes MYCBP2 and IRS2 was observed in DDLS; in vitro, these genes were essential for WDLS cell differentiation. This study defines a longitudinal model of liposarcomagenesis with initiation characterized by 12q13-15 amplification, early WDLS progression through inhibition of senescence by 6q23-25 amplification, and progression to DDLS driven by ATRX mutations and/or tertiary copy number events (e.g., 13q loss, 8q12-21 gain). Implications: This study defines the role of recurrent copy number alterations and gene mutations in WD/DDLS initiation and progression, creating a detailed map of molecular events regulating liposarcomagenesis, patient outcome, and dedifferentiation.

Molecular Cancer Research
National Institutes of Health (US), Memorial Sloan Kettering Cancer Center (US), The Netherlands Cancer Institute (NL), National Institutes of Health Clinical Center (US), University of Pennsylvania (US), Rockefeller University (US)
Johns Hopkins University, National Institutes of Health, National Cancer Institute
Good health and well-being
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon